0001193125-14-362098.txt : 20141002 0001193125-14-362098.hdr.sgml : 20141002 20141002160837 ACCESSION NUMBER: 0001193125-14-362098 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20141002 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20141002 DATE AS OF CHANGE: 20141002 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advanzeon Solutions, Inc. CENTRAL INDEX KEY: 0000022872 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 952594724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09927 FILM NUMBER: 141136490 BUSINESS ADDRESS: STREET 1: 3405 W. DR. MARTIN LUTHER KING JR. BLVD. STREET 2: SUITE 101 CITY: TAMPA STATE: FL ZIP: 33607 BUSINESS PHONE: 813-288-4808 MAIL ADDRESS: STREET 1: 3405 W. DR. MARTIN LUTHER KING JR. BLVD. STREET 2: SUITE 101 CITY: TAMPA STATE: FL ZIP: 33607 FORMER COMPANY: FORMER CONFORMED NAME: COMPREHENSIVE CARE CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: NEURO PSYCHIATRIC & HEALTH SERVICES DATE OF NAME CHANGE: 19730501 FORMER COMPANY: FORMER CONFORMED NAME: NEURO PSYCHIATRIC & HEALTH SERVICES INC DATE OF NAME CHANGE: 19700402 8-K 1 d799712d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 2, 2014

 

 

ADVANZEON SOLUTIONS, INC

(Exact Name of Registrant Specified in Charter)

 

Delaware   1-9927   95-2594724

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

2901 W. Busch Blvd, Suite 701

Tampa, Florida

  33618
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (813) 288-4808

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Items 8.01 Other Events and Regulation FD Disclosure.

Effective September 15, 2014, Advanzeon Solutions, Inc. appointed Dr. Mark Heidt as its President and elected him to its Board of Directors. Dr. Heidt succeeds Mr. Ramon Martinez who resigned as President and as a member of the Board of Directors for personal reasons.

Also, Mr. Jairo Estrada resigned from the Company’s Board of Directors effective August 31, 2014, for personal reasons.

 

Item 9.01 Financial Statements and Exhibits

 

  (a) Financial Statements

Not Applicable

 

  (b) Exhibits

 

  99.1 A copy of the press release entitled “Advanzeon Solutions, Inc. Elects Dr. Mark Heidt As President and Director” is attached.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ADVANZEON SOLUTIONS, INC.
Date: October 2, 2014     By:   /s/ Clark A. Marcus
        Clark A. Marcus, Chief Executive Officer
EX-99.1 2 d799712dex991.htm COPY OF PRESS RELEASE Copy of press release

Exhibit 99.1

 

LOGO

ADVANZEON SOLUTIONS, INC. ELECTS

DR. MARK HEIDT AS PRESIDENT AND DIRECTOR

TAMPA, FL, September 15, 2014 – Advanzeon Solutions, Inc. (OTC:BB: CHCR), (“Advanzeon” or the “Company”), which provides behavioral health, substance abuse and pharmacy management services, as well as sleep apnea programs, to employers, Taft-Hartley health and welfare funds, managed care companies throughout the U.S. is pleased to announce that Dr. Mark Heidt has agreed to join the Company as its new President and accepted his election to serve on the Company’s Board of Directors.

“We actively recruited Dr. Heidt to become the Company’s President and to accept a director’s position on the Board because of his leadership, background, practical savvy and drive to create and deliver the value promised to our customers and shareholders,” said Dr. Arnold Finestone, a member of the Company’s Board of Directors and Chairman of its Executive Search Committee. “As one of the nation’s premier experts in developing superior sales systems, mass marketing media programs, and recruiting, training and leading top-sales closing teams, Dr. Heidt brings to the Company over 35 years of hands-on, front line, technical, operational, and artistic core competency. Dr. Heidt is a nationally-recognized thought leader in designing innovative, resilient sales and marketing methods that have historically resulted in generating hundreds of thousands of new customers, positive cash-flow profits and high-profile branding opportunities for the industry iconic clients he has served with distinction.”

“I am excited and honored to join with a company that is so uniquely positioned in the right direction and primed to move to the next level of success,” said Dr. Heidt. “Having worked closely with the Company, its management and its staff for the past approximate eight months, I have seen, first hand, the potential of Advanzeon in our evolving healthcare environment including its expertise, dedication to quality and its perception for products needed in the healthcare industry. I believe its future is bright, and I am confident that I can assist the Company in achieving its potential in this new healthcare environment. I am particularly excited to work side-by-side with the Company’s leadership team, who truly understands what it takes to implement the key systems necessary to enable the Company to win in today’s high-tech, ultra-competitive marketing and sales environment. I share the Company’s belief that developing and strengthening the Company’s brand, infrastructure, abilities to acquire and retain customer loyalty, and enhancing customer experience is critical in meeting the Company’s objective of delivering value and success to its customers and shareholders.”

Mark Heidt was born in New York City and is an honors graduate of the Bronx High School of Science. He earned a dual Bachelor of Science Degree in Resource Business Management, again with honors, from Syracuse University, and the State University of New York College of Environmental Science and Forestry. He also earned a Juris Doctorate degree from Stetson University College of Law in Gulfport, FL.

About Advanzeon Solutions, Inc.

Established in 1969, Advanzeon provides behavioral health, substance abuse and pharmacy management services, as well as sleep apnea programs, for employers, Taft-Hartley health and welfare Funds, and managed care companies throughout the United States. Headquartered in Tampa, Florida, the Company focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches that address both the specific needs of


clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.advanzeon.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of the Company’s management, reflect numerous assumptions, and are subject to significant risks and uncertainties, many of which are beyond the Company’s control. If any of these underlying beliefs, expectations or assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

These risk factors include, among others, the ability of the Company to maximize its market share with new pharmacy initiatives, the ability of the Company’s new pharmacy cost-savings program to guarantee a 10% or more reduction in pharmacy costs, our ability to achieve expected results from new business and to revolutionize the pharmacy sector of the healthcare industry, the ability to obtain a performance bond on satisfactory terms, the ability of the Company’s pharmacy program to promote greater medication adherence without restricting access to needed medications, technological advances, challenges in development of new products and services, new products and services developed by competitors, the Company’s ability to provide superior patient care while increasing its business and margins as a result of implementing its pharmacy cost-savings program, general industry conditions and competition, general economic factors, global trends toward health care cost containment, the effect of governmental regulation, including pharmaceutical industry regulation, insurance regulation and health care legislation, varying trends in member pharmacy utilization, increases or variations in cost of care, seasonality, our ability to manage healthcare operating expenses, the profitability (if any) from capitated pharmacy contracts or other products, and the Company’s ability to obtain additional financing.

Advanzeon undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Additional risk factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s most recent Annual Report on Form 10-K and the Company’s other filings with the Securities and Exchange Commission (SEC), which are available at the SEC’s website at www.sec.gov.

GRAPHIC 3 g799712g70j14.jpg GRAPHIC begin 644 g799712g70j14.jpg M_]C_X``02D9)1@`!`0$`E@"6``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@ M0``9&5S8P`````````2D! M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+! M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H# MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P M!/X%#044%]@8&!A8&)P8W!D@& M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0) MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X- M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3 M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8# M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9 M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC M',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@ M;""8(,0@\"$<(4@A=2&A(B>K)]PH#2@_*'$H MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT, M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<-]1B)&9T:K1O!'-4=[1\!( M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4 MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5 M6^5<-5R&7-9=)UUX7&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I( M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5&YXS'DJ>8EYYWI& M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*" M](-7@[J$'82`A..%1X6KA@Z&I+CDTV3MI0@E(J4 M])5?EAMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H M4JC$J3>IJ:H_ MR#W(O,DZR;G*.,JWRS;+MLPUS+7--:6YQ_GJ>@RZ+SI1NG0ZEOJ MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0# M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1 M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1 M`Q$`/P#U6BBB@!K=*P=)U0WOB*^A).R,8C';Y3@G\2>O^%;DQQ$Q`R0#QZUP M7AFY2U\1('?*R@QANG)Z?F0*TA&Z9Q8BLX5*<>C9Z!2T@Z4M9G:%%%%`!111 M0`4444`%%)WI:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HI#4$-W%-<30QN"\)`<>F1_G\J!-I;E/5=3^ MQW-K;H%,D\H7![+D`G]:\]OHGM;N6$L=T;D!L8/!X-=+XMD,6M02#C8BL".H MPQJOXOT_,B:G;C?#,%W$#H<=3[$8_*NBG96OU/#Q+E6E.WV'^!TVA:K'JFG) M*N!*N%E4`@*WM[5I5Y9I&K2Z/?">,;D/$D?3&K*K'7*;;1X'AA9)KT MCY8P[U.]UB[?S'YCWL!\SL=S$8Z8X[=#BO0:TJQ47RKH,****R`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`0UQ MUIJ*V/BBZ#MMBED9&[`'/!/X_P`Z[$FN"\4P"/5Y)8]NR7G*GN!@@^_?\:UI MI-V9YN82E",:D>C-+QG;,1#=@-C[C9/3N/ZU%X8U2%[%2&)$>[H0?X?\ M^M1Z7K,-[IYTS5'(+#9',3GZ9)[CU_RM%&Z MY6_OTZUB:'KL^A7ARI,#,!+% MZ#/49Z$9_'I]-[1_%[0;;?55+(#@3*,D?[P[_P`^.]7=;T2S\167VO39(C.! ME)$QASW#=\\_Y[4I./N5-CNIQA+WZ6GD=%8WMO?VJ7-I*)(GY#`$?F#TJS7D M^@:O/X;ULP7F](-VRXB/...&`]HK"K3<'Y']7;R=;:VDG?[J*6->?#4+>74I+W4H7G9B2(@ M<`#MS[>E$(,Y^6('<1[M_ACK6=;>%M2NV\ MRYC-G;@[I)IN`BCDM@GZ_P"-=!_PFT%M%Y=MI6P#^$2A1^@KG]>\17^O,EF% M$43,,0Q!F+G(QG^]SC'\O3J@IK2*L*FXR=W*[.D^'[)+N" MU^WET[66EC+H'8R(X&.<]OH?\\UK3UT/,Q]X\LVKK9_,R;^SN;.4QW,3H?\` M:Z'_`!J?3O$%U8)]GD1+JV/!AFYP/0'L/TKI=/\`$-C?1"VU98XY?[S@;&XZ MY/0U+/X6T:_B,MKF/>20\3Y4G/-;>T6TT94/IG-7'5>X[^1V1IV=V MK,KZWK$.MV8DNXEM[Z$G0X(SZ\C=]*[3X>:G]N\/B"0L9K1O+8L2 M/N:LVN MWQD8#<(W<\NQX)]Q@D?7Z5Z%7.^!K>:+P^LMSE7N)6EV;-FSH``.P^7C'&#Q M71US59.4SL"BBBLP"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"J6I:;!J-N8IQS_"X'*_2KM%"=B914E:6QP=YX0U M")\6S),O0'.T@>^:H-HFOZ?*&ABF1CQN@?GGUP:])8X!)KE_$?B=[&9K6P5& MD7AI&Y"G'0#N:Z(5)RTW.">'HT?>O8YYM2\5V*%F:["D]980V?\`OH?RK/U' MQ%<:C`8-4M+>;&=DJJ4D0D]CZ''3'/%:UIXXOH)P;Z..XA)^;:H5A].WY_I7 M7"WT?7K7[1Y4%RC@#>!\WK@GJ,9Z=>:T!_^JMGPK:'1]5UAX;&:X"3^1$T>"``%7T1 MUU+3`S6RN&*XR8FSQSZ9Q]#^O7WLFK1(S:7901PN2^X$,S$\[O3G\:*LD]8] M36K/DA?7Y(BM_%UDUT(KNVEM7)VEWY`],]QU].*WY9E2`NJF3"[@JD9;Z5YA MK%Y>7T;6K>737TC59S`@'^BW(SNB;ZC'3J/Q[5$J.E MTU9NG^`H(;I9;VX%PB'B() M@$=L^WM57P3XB\[5IK.Z8[[C,@XP/,'W\`?WA\WL0>.>>\'-1*52G[MSK]G& M]["(NU0/2G445B6%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110!0U>Z>TL9'A3?,?EB7&E8)TW3M%T MQKW4XQ<7!&<,ZJ\:D^5"?+0>^> M3^?]*UIKF=CAQ3C#WWJ]D<_?R"[O&-O;"(,?DBB!.!V^I_K^5='X.AUW2=06 M.:RF%C.X61&0Y0]F'MV/_P!:MWPKX>CL8%O+E=US(O`;D1CV]_7_`/7GHI"P MC;RP"V#M!Z9K6I637(EH;48.,;O3'JQSN;KQZ`8'.*XZX M^W:]?$06L>_LL,8`49QS^/<^O:E3A%[['/.K-RY9/?H;TOA..ZL_M6EWRW$; M#]V,#GVR./7T]^]<9>126UPT4\962,_,C#KZCZ<]:[+1/#?B/2+C[5:SVP4X M,EJ[G#CN,@$`^A_/C(,GB_0IK_4UN84,:_9F>=P/E5D!*Y/P&:UA5496 M;NC54(Q5XJQ@16\.F>,-%GTV5S#=&.0`\E`Y*LOTP3UYQ7JPZ5Y3X%T=]2UJ M.Z?:T%@P<@Y^\9>*->9M;M&L#Y?V(AQCN^<]_;`_$UE3INI*R&E<]9I: MHZ=??VAI5O>6P0B5`P7?D#U&1Z?H%G:YTU%;4+5(9(U+/&K$[?;/K_`%XIH)!?VJ6T;_*LH?(#9&-V<8'7GG%;6L:_=V7F"WM$=X@6978 MX88SP0/3^E5*G*+LT#31T5%);A[1+B\M%A,B"1%5BWRGH<^XP:SK'Q?K M-]`)XM(@2%B0KO,P#8[#"D_CC%"IR=_(+';4M>>7?Q$O+2Z>W?3[=V0X+)*Q M&?\`OD&MF[\3WMKIHG>Q5)EA\V2.0LN.`V.G''K3=*:M?J%F=517":1XWU35 MY)8[33+;=#'YC%YFQMX]%-65\7:G'JEG;76F0K%0/K^%#I2 M3L]PY6=E17.ZMXML]-0NRLR@X'&-Y]A678^*]9U."2\M;&VM[16V*TH9RQZ] M00/3Z>])0DUS=`L]SM-5%^-/UV%;.4_=GB<^62>AP>0.>I].<51\ M77MP\$1L;B[AN1+Y:^5,RAP?49P>0/SIJF^9)Z7"VMF>@Y%&:\A\/^++_2]3 M(U"XN+FV<[)4EMN'DJ5$2XP0.>?QXJ?Q)<&WT:<@X+C8/?/7],UC^"6`D MO$[X0YSVYI)>XV*K6_VF%)>I1\6LUUJURH)Q9P`G=TY(Z?\`?0_*NB\.Z1'I MM@@9%-PXS(^!D9_ASZ"JE]`B^*X/.MUDAO8#$V>F1SS^0%=$.:ZD50I?O M)3>]Q0*CN(([BWD@E7(M&FBT^UO?+9[AR3=$#!WMENWIDC\JZW4[Z[GU2UTNPM+.2YD4 MS.+M69%4="<9[C\\>M3SQ>)/*"2W-C#*1]Z"V:0#\7;^E=-*3IV92NC/^'&I M3+I\UA=JT:PMOB9UVC!ZKG&.O/KR:;XIB:ZT.XAMXB\C,N`O4_,#_*N?A\6: MS9:U''J4X>.&;;<(MO'D@'D#Y1[^E=9XKO[JRT2YGM@D4B,H5Q&I/+@=QZ&G M*$E53MN-IWN9GA!$T_0)X+]/*F:X\Q%(R2"H'X5E^(M*FU'5DN]-VKE!N;.T M[P3R/PQS70^"=7O[[0YY+F=YY1<[5).,#:./IS^M<_XFUK5+_P`1BSTR^N5* MJL0C@F9`7R8W[BT%[H2V2\%P@5U0L6##H0=OUX]ZZ^&VGL]&AB,KRRQ1@.Y8L7..3 MD\]?6O/O&<^J:=K,=W#=7,44WS*JR$+N7&1C.!V/OD_2HI7G>">Y*UT.HETR M2ZU"SE>,BWMV\TQ@']X_\.>V!C-1Z[H=QJEN+9"\,;$L[>622<':/IG!_#M4 MNF-GZU"NM;[`3>%-$O?#LTV9)+B&9`#&(B/F!X.>?4CCU'M6KJ,Y2?+@C`Q\O/Y$]S4TJ;FWKH@2NSJM&\"FQU:.[O+@W, M7Y1&X]LG/X^];NN6$M_:W<4*#?/$44N",$C'.!3X$A\/:'!96[@1VZ?O)6^5 M<]23GIDDG';-9BZQ-JFAZG=QM(D3>:L+CY650F,@^N1G\:ERG-\SZ!JRAX5T M"]T*:YFN6CD,L853$S9XSQR![5J6ENJZ1#'?H6NUE,C;2<*=Y8`'V!Q^E<_\ M/]0O[K4[J&6XDE)@WCS9&(&&QQG@?>%;UUJDWA_0F2>0,ZLXA+R%FK:EJ2M:6I>W1`J'S$`)ZDX)'^17:Z-;06?A:V MLC@.L`+)UPYY8&[P'N%7RI<_,2ZX&2<=2,'\:*G,Z<>PG\)R?C?3[FX>TDM+*>0JKAS M'$S8'!&2.G4U8C>67PWI4DT+"5+F)6W+@G#E?P_&D\6>)M2M-3AL=,D$4@`W MJL2-N+?='(/^2*VYM6U#3M/T\SJKRR311RET"[B?O=,8/7\A]*IN2A%->@]; M(YSQEH9UP1Z=-IEV%VF)A;N>,$Y^7]># M^'?CU2X\Q8-T2*SCKD5Y[XNC^PA98]"T[[,YQO6`HR-[E6'7G&?_`*Y=*ISQ M]G)`G=69VOA)R_A732QSBW51QC@#`_045'X5#2>&[&1&,:M""(P!M7Z9R?S) MHKEG\3)>YMT445(B*X02V\B'&&4CFLOPLP.BQQ_Q1LR,/[IR3C\B*UVY&*R] M'C%M>:C;C/\`K_-''&'`/\P:KI8QE']Y&7JBMXQS_9,>.AF&?R-87A*<0ZX% M8X\V-D'N>#_0UT7BJ+S-&74EG MJ2:C8_*MP!*F_O66U0_PED8X/OS5^BJE)RU8V[GGVI>`= M1U'4)KR>_MEDE;+!$8#ICC\JT+?P=!=*BBDBCFO$20895FP#QCTK3TSP_I6EX:SM(TDV@> M81ENF.O;/M6:=4GN=7N+9KX621DI'\@(8@XYS5I-5FLM-DFU%#YHF9$`_P"6 M@[$>W7GVI-S>[.18R$K]E?\``W.,8JAJ6D6FIK`MVFX03+*F/4=C[>HJM+K$ MUJ8FOK3RHI2`'5\X/N,#%)'K,DFKFP2W0XY\SS>",`^GH:236J*^LTT[7U_S M+>HZ39:I;_9[Z(RQ9R5$C*#]=I&?I2:;I%EI<31V*R1HV,JTSN!UZ!B<=>U) MK&HMIMH+@1"0%MI&[;CWZ5%)J<\=E;7'V5?](=5QYOW=QP.W-)7L7*M!-Q;V M([WPMHVH7)N+VW>>0G(+W$A`[X`W8`]AQ3&\*:6+5K:V%Q:1/G>D$[`.",8( M)((IDOB&>$1M)8!4E8JC&;[V#C/3I2S:__P!S M/ZY25]=O4L:-H%MHV%M;B[:(`A8I)=R+DYX':KM[907EK);3KNCE4HX'&0?> ML^;7!'%:[8"\]RH9(PW`!Z9/_P!:G)K#K?"SN[<0S/\`ZH[\JWX]JFTKW']9 MIWM%X&,#I@=!QCVZ5CP^!-(@??!->1O_`'DFVG\P M*N67B`7%^UI/;^3("5'[S(+#MG%+)KCQ6R.]LHEDF,2IYO&0<$DX[526599GNY77O)+DG]*L6%_=IH3:C/ M(;AADLK80``]1@>U21Z^L^GR3P0;I8L>9$SXP#W!Q3YI]S..+@TM;75_D:[P MQNC+(BLK=0PR#6-_PB>EQR/):"XLF^MQ=6">-L9 M_P`]15%MR.'1F5@<@J<$'\*[.W2U\5:1YDFQ+V)=C,.H/J0/X3_C[UO/W=>A MRTZ7MXIQ?O(GT+Q/#>X@O-L-QD`'HK_3T^A_"NC%>5:KIMSILYBN4QGHP^ZP M^M6]'\47FF;8IQ_S^'6LY4;J\#T*&*DOAI)&<=)4IM^VWO7J)S MFF/HBMC&H7ZCN!.>?SI\?B#199EABU>P>5F"JBW*$ECT`&>M6X[NWEN);>*: M-YH<>9&K`LF>1D=1GM1=F3H4WNC+E\.0NV?M=T/0&38 M%"H4C'<>_M6Q13YF2L+24N9+4Y*X6QU&>Z%X_P!FN(9&`D`($BCID'OC_'FJ M#VMX^B0RE"T4,C%1C^$@'/TX/YUVYB0_>4'ZBG[?:J4['++`*;;;U?8YC7+R M'5+6VM['=-(\@;`!^7@C!].M5[6:"V\4!Y9T\M$V&0GC(0#^8KK5BC3.U%7/ M7`ZT[:/2ES:6*>$E*:FY:W73L17EGIEK M;L7E62-W`'W`AYSZ=/UKH\4U(D3.Q`N>N!BCFTL7]6DY\[ENK,YKQ;+%]HLX M]Z[T8LR^@)'/Z5-XJGADTF,)(A+R!EPP^8`')%=#M%&!1S;!/#.7/K\1QZD6 MUUIFHOAH/)5"X&0I"D'./3!_R*M7SIJ.O6TENRF"W`=Y<_+USUZ=JZ4H&&"` M1Z4)&J#"*%'M1SD?4].6^C:?W'*FQAU6QN)K-U-PD\C*5;E@6)`]O44T"*72 M[2#4Y M4LUS9QC"M&,@GJ,'Z9XZ?S.KJFHVT_AV259`!,A"!N"3G&,5H75F)[5H$'J0BZ=]+',V]Y;_P#"&3PF M:/S"CJ%W#.3G%1ZQ8""5+^Q;=;38WE6!')_D:Z_:/2@J",$`BCGU)>"4H*,G MLE;Y'+6+?V5K]S]M78DV2LI!(/(/7M_CBM*;6[6*.:>..29$*KO1>&)SP">N M/ZUJM&CC#J&'H108D*[2J[?3%#:>K-*="=*+C"6G30R+S2_[6>*Y2[DB0H,* M%_'UHB\.0HVXW=T3Z!\#_&MH4M+F9;PM)OF:U,E-$5P34;"2W?@D94_W6'0U=I#TIIV)E%233/)KJ)X)Y()5*NAPP([T:7?R:3J<= MY'R%.'3^\IZC^OU`KJ?&VD$K_:=N.5&)AZ]@W]/RKBF8'ZUWP:G$\3V4L/4T M/6"MEJ]@I*K/;RKD$CJ"/S!_6N/USP?-"7GT[,L?)\L_>'?CUX_&J'ASQ--I M#K;W.9+,GD#K'UR1^)R1_6O1[>>&YB22"171ERI4]17,^>B]#U$H5XW>YXXD MUS8W/F02-#/&>JG!'8_UKN/#7B]=0F6QU$+%<,<1R+PK^WL?T/Z5KZUX:T_5 MU9Y8_+G(^65.".G7UZ#\NHKSKQ!X>O=$DW2KYEN3@3+T_'T__76ZE3KJST8X M0E3]#I=3\)ZC.NK'3X;"WDN;FW>VD69U:-(E`ZJF0>!G6\*:/J.F7 M&H2ZF]N\EW(DA>%RVYMN&)!1<#/(`SC..V3C>"O% MXKR[Q1H[Z1?D*/\`1YB6B;^:_A_GT'JE9NOZ8FJZ:]N>'^]&V2-K8XZ=JUI5 M.27D95::FCR$OV/!K7\->(IM$O`LCLUG(?WD?H>S#W]?4?AC&NHW@FDAE4K) M&Q5E/!!'6DMH);I)_*4L8(S*_L@."?PR/\@UZ4HQE'78RIP:U1[;;7$-U;QS M02+)&Z[E93D$4Z:)98F1U#JW!5AD$5YOX`\0-97HTJY8?9YV_=,W&QSV_$\? M7'J:]+'2O,J4W3E8ZCR?Q;X>DT"]2[LBPMF?=&02&B;.<9_4=^*]&\-Z@=4T M&UO&SO=,/G'W@<']13]/0XK%^&YF/A8"4<+/(( M_P#=S_CD?A6DZGM*>NZ'T.JHHHKG$%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%)2T4`>;_$; M3!;WL>H1KB.<8D.#@..Y/09'\C6!X5NFL_%%BXP-THC.X=F^4_SKTKQI9?;? M#5RJ@%XAYR$]MO)_'&1^->5:/_R'K#:,_P"DQ\?\"%>C0ESTFGT"*LS8\9:, M="UA+BUW1V\QWQ$$@HPZC/7W!]^M>HZ=<"[TZVN@"HFB60`XXR`>WUKG_B'9 MQ7'A:6>0D-;R(ZD8[D*1]#G]!Z5O:3;_`&32+.U!W"&!(\^N%`_I7)4GSPC? M=#Z%HC(J"RL[>PM5M[5-D2YP,D]?<\FK%%8B"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"HI) M3&>8V*^HJ6B@"N+N(]?457:S9#NB;IT'>@":]A M^TV)].2)0<3JQ&-QZG/L./\`@5=5&7+"3&G8]`N;6&\M M3!]2Z9I\&F64=K;*0D8QSU)[ MD^]6Z*=W:P!1112`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H 9HHH`****`"BBB@`HHHH`****`"BBB@#_V3\_ ` end